Last Price$33.90.6%
Market Cap$15.2B
P/EBIT LTM
7.3x
5Y avg
13.1x
Biotechnology industry
median
(1.7x)
Stock quality & Intrinsic value
6/10
4.3% undervalued
Royalty Pharma plc P/EBIT LTM
Annual
Quarterly
Daily
Crunching data... Almost there!
| Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|
| P/EBIT LTM | 7.3x | 10.8x | 22.1x | 12.9x | 7.3x |
Overvalued or undervalued?
Check the intrinsic value for RPRX
and see if it's the right time to invest.
Royalty Pharma plc (RPRX) P/EBIT LTM comparison analysis
General
LTM P/EBIT LTM
OTHER METRICS
Company name
Revenue growth
EPS growth
Net Income margin
Royalty Pharma plcRPRX
11.8x
(3.8%)
(43.7%)
37.9%
Median Peer Set
(14.9x)
18.9%
(47.6%)
0.4%
Incyte CorporationINCY
237.4x
14.8%
(94.0%)
0.8%
Novo Nordisk A/SNVO
22.4x
24.9%
142.8%
34.8%
Regeneron Pharmaceuticals, Inc.REGN
18.4x
8.3%
10.4%
31.1%
United Therapeutics CorporationUTHR
10.2x
23.6%
25.7%
41.5%
BeiGene, Ltd.BGNE
(2.1x)
73.7%
(56.5%)
(35.9%)
BioNTech SEBNTX
(27.6x)
(77.4%)
(89.7%)
24.4%
Summit Therapeutics Inc.SMMT
(69.1x)
N/A
(68.7%)
N/A
argenx SEARGX
(98.8x)
198.6%
(60.5%)
(24.1%)
Alnylam Pharmaceuticals, Inc.ALNY
(177.0x)
23.0%
(38.6%)
(12.4%)
Vertex Pharmaceuticals IncorporatedVRTX
(508.6x)
11.7%
N/A
(4.9%)
RPRX key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|
% growth | 1,652.4 0.0% | 1,877.4 13.6% | 1,597.9 (14.9%) | 1,794.9 12.3% | 1,814.3 1.1% | 2,122.0 17.0% | 2,289.5 7.9% | 2,237.2 (2.3%) | 2,354.6 5.2% | 2,264.0 (3.8%) |
| Cost of Goods Sold (COGS) | 0.0 | 0.0 | 33.3 | 136.0 | 1,019.3 | 88.1 | 23.0 | 5.7 | 560.7 | 0.0 |
% margin | 1,652.4 100.0% | 1,877.4 100.0% | 1,564.7 97.9% | 1,658.9 92.4% | 794.9 43.8% | 2,033.9 95.8% | 2,266.5 99.0% | 2,231.5 99.7% | 1,793.9 76.2% | 2,264.0 100.0% |
| Operating Expenses | 790.0 | 1,086.3 | 658.2 | 430.4 | (808.9) | 527.0 | 858.7 | 1,314.3 | 862.4 | 971.0 |
| Research & Development Expenses (R&D) | 98.4 | 91.0 | 117.9 | 392.6 | 83.0 | 26.0 | 200.1 | 177.1 | 52.0 | 2.0 |
| Selling, General & Administrative Expenses (SG&A) | 121.4 | 69.5 | 106.4 | 61.9 | 103.4 | 182.0 | 182.8 | 227.3 | 249.7 | 237.0 |
% margin | 794.3 48.1% | 722.9 38.5% | 939.7 58.8% | 1,364.4 76.0% | 2,623.2 144.6% | 1,595.0 75.2% | 1,430.7 62.5% | 977.5 43.7% | 1,492.2 63.4% | 1,292.0 57.1% |
| Interest Income | 0.0 | 0.0 | 6.8 | 24.4 | 22.3 | 28.4 | 53.5 | 78.3 | 72.3 | 0.0 |
| Interest Expense | 224.4 | 238.9 | 247.3 | 280.0 | 268.6 | 157.0 | 166.1 | 188.0 | 187.2 | 226.0 |
| Pre-tax Income | 758.7 | 761.9 | 1,343.2 | 1,517.9 | 2,461.4 | 1,702.0 | 1,241.2 | 230.1 | 1,700.1 | 1,331.0 |
% effective tax rate | 177.3 23.4% | 196.0 25.7% | 542.7 40.4% | 433.4 28.6% | 349.3 14.2% | 1,147.0 67.4% | 762.4 61.4% | 187.2 81.4% | 0.0 0.0% | 472.0 35.5% |
% margin | 581.4 35.2% | 565.9 30.1% | 1,210.0 75.7% | 1,377.7 76.8% | 2,348.5 129.4% | 495.2 23.3% | 478.8 20.9% | 42.8 1.9% | 1,134.8 48.2% | 859.0 37.9% |
| EPS | 0.96 | 0.93 | 3.42 | 3.89 | 6.42 | 1.32 | 1.15 | 0.10 | 3.41 | 1.92 |
| Diluted EPS | 0.96 | 0.93 | 3.42 | 3.89 | 6.42 | 1.32 | 1.15 | 0.10 | 2.53 | 1.45 |
% margin | 862.4 52.2% | 1,069.0 56.9% | 973.0 60.9% | 1,397.7 77.9% | 2,647.1 145.9% | 1,683.5 79.3% | 1,453.7 63.5% | 928.6 41.5% | 1,887.3 80.2% | 1,292.0 57.1% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is Royalty Pharma plc's P/EBIT LTM?
As of today, Microsoft Corp's last 12-month P/EBIT LTM is 7.3x, based on the financial report for Dec 30, 2024 (Q4’2024). The average annual P/EBIT LTM for Royalty Pharma plc have been 14.5x over the past three years, and 12.4x over the past five years.
2) Is Royalty Pharma plc's P/EBIT LTM Good?
As of today, Royalty Pharma plc's P/EBIT LTM is 7.3x, which is higher than industry median of (1.7x). It indicates that Royalty Pharma plc's P/EBIT LTM is Bad.